**COMET: K1-/K2-Centres**

**Oncotyrol**

Oncotyrol-Center for Personalized Cancer Medicine

<table>
<thead>
<tr>
<th>Main location</th>
<th>Innsbruck, Tirol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other locations</td>
<td>Hall, Tirol</td>
</tr>
<tr>
<td></td>
<td>Salzburg, Salzburg</td>
</tr>
<tr>
<td>Research programme</td>
<td>Oncotyrol is a partnership to accelerate the development and evaluation of individualized cancer therapies, along with prognostic and preventive methods. Research Focus lies on breast cancer, prostate cancer and leukemia (esp. multiple myeloma).</td>
</tr>
</tbody>
</table>

**Planned realisation and outcomes**

- Discovery and validation of new biomarkers and drug targets
- Development of new assays for biomarkers and drug screening methods
- Development of new treatment strategies
- Development of new methods to assess the socioeconomic impact of diagnostic and therapeutic strategies
- Development of clinical registries and clinical software solutions

**History of establishment**
The K1-Centre Oncotyrol developed out of the K-project KMT in 2008, was successfully evaluated in 2011 and entered the 2nd funding period into 2012. The new funding period is scheduled to start in 2015.

**Selected company partners** (max. 10)
1. Abbvie Deutschland GmbH & Co. KG, Wiesbaden
2. World-Direct
3. ELEKTA GmbH
4. TILAK - Tiroler Landeskrankenanstalten GmbH
5. Janssen - Cilag Pharma GmbH
6. Fraunhofer Institute IGD
7. Novartis Pharma GmbH
8. OROBOROS INSTRUMENTS GmbH
9. THERACODE GmbH
10. Evaluation Software Development

**Selected scientific partners** (max. 5)
1. Medizinische Universität Innsbruck
2. UMIT - The Health and Life Sciences University
3. University Clinics for Internal Medicine III (Salzburg)
4. Fred Hutchinson Cancer Research Center, USA
5. University of Utah, USA

**Selected international partners** *(max. 5)*
1. Amgen GmbH (Europe)
2. MARKES Instruments Ltd., UK
3. Dr. Schär AG, Italy
4. Vichem Chemie Kft, Hungary
5. Biodesix, Inc., USA

**Duration of the K1-/K2-Centre**
July 2008 – Juni 2015  (7 years)

**Staff employed at the Centre**
31 FTE  (thereof 26 scientists)

**Total costs**
- 1st Funding period: EUR 23,1 Mio (4 years)
- 2nd Funding period: EUR 13,5 Mio (3 years)

**Management of the Centre**
Bernhard Hofer, MSc; Oncotyrol GmbH, CEO

**Contact:**
Karl-Kapfererstr. 5/3 6020 Innsbruck
++ 43 512 576523;  e-mail: office@oncotyrol.at;  www.oncotyrol.at

---

1 Partners with headquarters outside Austria